A 26-week, randomised, open-label, multinational, treat-to-target trial comparing efficacy and safety of insulin degludec/insulin aspart once daily (OD) and insulin glargine OD both in combination with metformin in insulin-naive subjects with type 2 diabetes inadequately controlled on oral antidiabetic drugs (OADs)

Trial Profile

A 26-week, randomised, open-label, multinational, treat-to-target trial comparing efficacy and safety of insulin degludec/insulin aspart once daily (OD) and insulin glargine OD both in combination with metformin in insulin-naive subjects with type 2 diabetes inadequately controlled on oral antidiabetic drugs (OADs)

Suspended
Phase of Trial: Phase III

Latest Information Update: 04 Dec 2015

At a glance

  • Drugs Insulin degludec/insulin aspart (Primary) ; Insulin glargine; Metformin
  • Indications Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Acronyms BOOST; BOOST-START-2
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 01 Dec 2015 Post-hoc pooled analysis results presented at the 23rd World Diabetes Congress of the International Diabetes Federation (IDF), as per Novo Nordisk media release.
    • 09 Feb 2013 Status changed from recruiting to suspended as reported by European Clinical Trials Database.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top